Chandigarh, July 9 (IBNS): Venus Remedies Limited, a leading research based global pharmaceutical company, on Monday said it has introduced for the first time a nanotechnology based “Ready-to-Use” Single Vial Docetaxel in the domestic market under the brand name “TAXEDOL”.
Dr. Mufti Suhail Sayeed, VP-VMRC, Venus Remedies Limited, said, “TAXEDOL is ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml. Our one-vial formulation and is having the advantage of requiring a single dilution step in suitable infusion solutions prior to administration. Thus, offering cost-effective solution to patients.”
TAXEDOL (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product.
This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff.
Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.
The formulation comprises of Docetaxel in nano particle form which gives 11% higher cancer cell killing potential as compared to existing Docetaxel.
“We have received very positive response from the medical fraternity especially for the 120mg strength as it is convenient not only for the medical staff but also for the patient,” said Suhail.
A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.
“TAXEDOL, a 'Ready-to-Use' single vial will not only weed out the competition from other players in the market but is hopeful of capturing significant share in Rs 1,500 crore Indian Cancer Drug Industry, which is speculated to show a steady growth over the coming few years,” said Dheeraj Aggarwal, CFO, Venus Remedies Limited.
"Besides this, we are successfully marketing Docetaxel under the brand name 'DOXOL' in the various emerging markets of Africa, Asia, CIS and LAC," he said.
The company said it is also contributing successfully in the oncology segment for Europe and ROW through its wide array of key products, which includes Bortezomib, Pemeterxed, Paclitaxel, Gemcitabine to name a few.
